Merck’s Covid-19 Pill Gets Negative Recommendation in EU
- Drug has long faced concerns on safety, effectiveness
- Number of Covid treatments decreasing as variants spread
This article is for subscribers only.
Merck & Co.’s Covid-19 pill received a negative recommendation from a European Union regulatory committee, a blow to efforts to gain clearance for marketing the medicine in the bloc.
The EU’s Committee for Medicinal Products for Human Use couldn’t conclude that the drug, Lagevrio, reduces the risk of hospitalization or death or shortens the duration of illness or time to recovery in adults at risk of severe disease, according to a statement Friday.